Publication Name	World Journal of Gastroenterology
Manuscript ID	9719
Country	Türkiye

Received	2014-02-25 11:37
Peer-Review Started	2014-02-25 12:58
To Make the First Decision	2014-03-27 20:57
Return for Revision	2014-03-31 10:23
Revised	2014-04-22 00:00
Second Decision	2014-05-26 21:20
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-05-26 21:38
Articles in Press	2014-05-26 22:00
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-06-02 00:45
Typeset the Manuscript	2014-10-09 15:36
Publish the Manuscript Online	2014-10-20 18:35

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning?
Manuscript Source	Invited Manuscript
All Author List	Bülent Baran and Filiz Akyüz
Funding Agency and Grant Number
Corresponding Author	Filiz Akyuz, MD, Professor, Division of Gastroenterohepatology, Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, Capa, 34093 Istanbul, Turkey. filizakyuz@hotmail.com
Key Words	Non-alcoholic steatohepatitis; Pathogenesis; Inflammation; Fibrosis; Life-style changes; Pharmacologic treatment
Core Tip	Many clinical studies have tried numerous drugs and alternative medicine, but investigators have failed to identify a safe and effective therapy for patients with non-alcoholic steatohepatitis (NASH). As summarized, the heterogeneity of pathogenic pathways in individual patients with NASH may warrant the development of an individualized treatment according to the underlying pathogenic pathway. The differentiation of pathogenetic targets may require the development of diagnostic and prognostic biomarkers, and the identification of genetic susceptibilities. At present, evidence-based medicine provides only a few options including life-style modifications targeting weight loss, pioglitazone and vitamin E in non-diabetic patients with biopsy-proven NASH.
Publish Date	2014-10-20 18:35
Citation	Baran B, Akyüz F. Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning? World J Gastroenterol 2014; 20(39): 14219-14229
URL	http://www.wjgnet.com/1007-9327/full/v20/i39/14219.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i39.14219

Full Article (PDF)	WJG-20-14219.pdf
Full Article (Word)	WJG-20-14219.doc
Manuscript File	9719-Review.docx
Answering Reviewers	9719-Answering reviewers.pdf
Copyright License Agreement	9719-Copyright assignment.pdf
Peer-review Report	9719-Peer reviews.pdf
Scientific Misconduct Check	9719-CrossCheck.jpg
Scientific Editor Work List	9719-Scientific editor work list.pdf